First City Capital Management Inc. Trims Position in Sanofi (NASDAQ:SNY)

First City Capital Management Inc. lowered its position in Sanofi (NASDAQ:SNY) by 29.8% in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 13,970 shares of the company’s stock after selling 5,936 shares during the quarter. First City Capital Management Inc.’s holdings in Sanofi were worth $678,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently bought and sold shares of SNY. Vestal Point Capital LP purchased a new stake in shares of Sanofi in the 4th quarter valued at approximately $14,919,000. Dynamic Advisor Solutions LLC increased its stake in Sanofi by 39.2% during the first quarter. Dynamic Advisor Solutions LLC now owns 57,204 shares of the company’s stock worth $2,780,000 after acquiring an additional 16,117 shares during the last quarter. Manning & Napier Advisors LLC purchased a new stake in Sanofi in the second quarter valued at $13,725,000. Mount Yale Investment Advisors LLC lifted its stake in shares of Sanofi by 44.3% in the 1st quarter. Mount Yale Investment Advisors LLC now owns 41,707 shares of the company’s stock valued at $2,027,000 after purchasing an additional 12,806 shares during the last quarter. Finally, Jennison Associates LLC grew its holdings in shares of Sanofi by 18.9% during the 1st quarter. Jennison Associates LLC now owns 189,622 shares of the company’s stock worth $9,216,000 after purchasing an additional 30,115 shares during the period. 10.04% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several analysts recently issued reports on SNY shares. StockNews.com upgraded shares of Sanofi from a “buy” rating to a “strong-buy” rating in a report on Friday. Citigroup raised shares of Sanofi to a “strong-buy” rating in a research note on Tuesday, September 17th. Finally, Argus lifted their target price on shares of Sanofi from $55.00 to $60.00 and gave the company a “buy” rating in a report on Friday, July 26th. Three research analysts have rated the stock with a hold rating, one has assigned a buy rating and two have given a strong buy rating to the stock. According to MarketBeat.com, Sanofi currently has an average rating of “Moderate Buy” and a consensus target price of $57.50.

Sanofi Trading Down 1.1 %

NASDAQ SNY opened at $57.63 on Friday. The company has a debt-to-equity ratio of 0.17, a quick ratio of 0.65 and a current ratio of 1.00. The firm has a market cap of $145.96 billion, a price-to-earnings ratio of 28.96, a PEG ratio of 1.62 and a beta of 0.60. The firm has a 50 day simple moving average of $54.34 and a 200-day simple moving average of $50.48. Sanofi has a one year low of $42.63 and a one year high of $58.97.

Sanofi (NASDAQ:SNY) last released its earnings results on Thursday, July 25th. The company reported $0.93 EPS for the quarter, topping the consensus estimate of $0.88 by $0.05. The firm had revenue of $10.75 billion during the quarter, compared to analysts’ expectations of $16.86 billion. Sanofi had a return on equity of 26.29% and a net margin of 9.60%. Sanofi’s revenue for the quarter was up 7.8% on a year-over-year basis. During the same period in the previous year, the firm posted $0.95 EPS. Equities research analysts anticipate that Sanofi will post 4.25 EPS for the current fiscal year.

About Sanofi

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.